预测性帕金森病快速进展的预测因素:长度随访研究
Peng Liu1, Linxi Chen1,2, Xinwei He1
1Department of Neurology, Taizhou Central Hospital, Taizhou University Hospital, Taizhou, China.
Gerontology
|April 2, 2024
概括
某些预发性帕金森病 (PD) 患者的进展很快. 运动障碍学会统一帕金森病评分表第二部分 (MDS-UPDRS II) 评分和宾夕法尼亚大学气味识别测试 (UPSIT) 评分预测PD进展速度更快.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
背景情况:
- 帕金森病 (PD) 在运动症状显现之前呈现出一种前兆阶段.
- 在prodromal PD持续时间和临床特征方面存在显著的异质性,这表明进展率各不相同.
- 识别预测器的快速进展在prodromal PD对于及时干预至关重要.
研究的目的:
- 为了确定预测患有前发性帕金森病的个体快速疾病进展的临床因素.
- 分析来自帕金森氏症进展标志物倡议 (PPMI) 的数据,以预测出发性PD进展的预测因素.
主要方法:
- 从PPMI队列中对61名前发性PD患者进行了回顾性分析.
- 评估基线特征,包括REM睡眠行为障碍 (RBD) 和低血 (UPSIT).
- 使用MDS-UPDRS得分对疾病进展的纵向评估.
主要成果:
- 21.3%的前发性PD参与者表现出快速进展.
- 在快速和非快速进展组中,MDS-UPDRS II分数和UPSIT分数显著不同.
- 纵向分析显示,快速进展组的MDS-UPDRS III和总得分增加.
- 回归分析确定了MDS-UPDRS II和UPSIT分数作为快速进展的预测指标.
结论:
- MDS-UPDRS II分数和UPSIT分数可以作为PD快速进展的早期临床标记.
- 需要对精确的生物标志物和先进的评估方法进行进一步的研究.
- 了解prodromal PD异质性可以改善患者管理策略.
更多相关视频
10:28Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.2K
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
相关概念视频
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
610
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
610
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
